| 韩璐戴广海1 汪进良1 孙刚2△.70 岁以上老年原发性肝癌患者临床特点[J].,2012,12(12):2322-2326 |
| 70 岁以上老年原发性肝癌患者临床特点 |
| Clinical Features and Prognosis of Primary Liver Cancer in ElderlyPatients Over 70 Years Old |
| |
| DOI： |
| 中文关键词: 老年 原发性肝癌 肝动脉化疗栓塞 预后 |
| 英文关键词: Elderly Primary liver cancer TACE Prognosis |
| 基金项目: |
|
| 摘要点击次数: 754 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨70 岁以上高龄原发性肝癌患者临床表现、诊治方法和预后特点。方法：回顾性研究我院2000～2010 年间70 例
原发性肝癌患者（PLC）临床资料，比较两组患者（≥70 岁，高龄组；和＜70 岁，低龄组）的临床特点和预后。结果：≥70 岁患者36
例（51.4%），＜70 岁34 例（48.6%）。与低龄组相比，高龄组心脏病（50.0% vs 17.6%）和糖尿病（41.7% vs 14.7%）显著增高
（P=0.004-0.012）；而乙型病毒性肝炎感染率低（50.0% vs 88.2%，P=0.016），发病时平均肿瘤直径小（3.4±2.3cm vs 5.8±4.4cm，
P=0.02）。两组男性发病率、饮酒、脑血管病、首发症状和体征、肝硬化、肿瘤位置、肿瘤形态、AFP、发病时Child 分级、组织学类型两
组无显著差异（P＞0.05）。总体（59，84.3%）以肝动脉化疗栓塞（TACE）治疗为主，平均治疗3.2±3.1 次，两组接受TACE 治疗患者
和次数无差异。平均随访28.9 月，生存分析显示两组死亡率(63.9% vs 58.8%，p=0.66)和中位生存时间（25.5 月vs 20.5 月，P=0.88）
无显著差异。结论：≥70 岁高龄PLC 患者有较高的心脏病和糖尿病合并率，但多数可耐受系统性TACE 治疗，从而有效延长老年
患者的平均生存时间。 |
| 英文摘要: |
| Objective: To investigate the clinical characteristics, diagnosis, treatments and prognosis of Primary liver cancer
(PLC) in patients over seventy years old. Methods: A total of eligible 70 PLC patients from a tertiary hospital were indentified from 2000
to 2010. The clinical data and follow-up information of these patients were reviewed and retrieved. We compared these clinical features
in patients at an advanced age more than 70 year (≥70 group) and those less than 70 year old (＜70 group). Results: 36 cases (51.4%)
were in≥70 group and 34 (48.6%) in＜70 group. Compared with younger patients, there were higher comorbid rates of cardiovascular
disease (50.0% vs 17.6%) and diabetes mellitus (41.7% vs 14.7%), (P= 0.004-0.012) . However, the incidence of viral hepatitis type B
(50.0% vs 88.2%，P=0.016) and diameter of PLC mass at the initial diagnose (3.4±2.3cm vs 5.8±4.4cm，P=0.02) were lower. There
were no significant differences between two groups regarding baseline data including male sex, alcohol abuse, cerebrovascular disease,
initial symptoms and physical signs, tumor location, tumor shape, AFP level, Child-Pugh score, and histopathologic results. Totally 59
cases (84.3%) received 3.2±3.1times transarterial chemoembolization (TACE). During the mean 28.9 months follow-up, survival outcomes
showed that individual cumulative mortality (63.9% vs 58.8%, P= 0.66) and median survival duration (25.5 months vs 20.5 months,
P = 0.88) were similar between two groups. Conclusion: Despite a higher comorbid rate of cardiovascular disease and diabetes mellitus,
the curative TACE may still be feasible and provide survival benefits for major of PLC patients of advanced age more than 70 years old. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
